Raza Hoda, MD, FASCP, discusses characterizing hormone receptor–positive, HER2-low, -ultralow, and -null breast carcinoma in the metastatic setting.
Raza Hoda, MD, FASCP
Advertisement
Articles by Raza Hoda, MD, FASCP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Full Approval to Afami-Cel for Advanced Synovial Sarcoma
2
Venetoclax/Ibrutinib Clears Resistance Mutations in BTK Inhibitor–Resistant CLL
3
Dose-Modified, Fixed-Duration Ibrutinib Plus Venetoclax Meets ORR End Point in Untreated CLL
4
Sigvotatug Vedotin Fails to Improve OS in Advanced, Pretreated Nonsquamous NSCLC
5